Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bearish
Daily trend turns up above $0.75
Key levels
Resistance$0.75
Resistance$0.62
Support$0.51
Support$0.39
Latest news & SEC filings
AnalystBarclays keeps Equal-Weight on Humacyte, lifts price target to $0.6
ProductHumacyte Shares Findings on Bioengineered Blood Vessel at VEITH 2026
AnalystBTIG Reiterates Buy Rating on Humacyte With $2 Price Target
All HUMA news →Humacyte is a commercial-stage biotechnology company that develops and manufactures bioengineered human tissues. Its lead product, Symvess, is an acellular tissue engineered vessel approved for treating extremity arterial injuries in adults. The company also runs clinical programs for dialysis access and peripheral artery disease, and is exploring uses in heart surgery and Type 1 diabetes. It operates a manufacturing facility in the United States.
Based on the company's 10-K filed Mar 27, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.50
SEPT Mid Target
$1.25
SEPT High Target
$4.00
Analyst Consensus
$1.25
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for HUMA.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1.02
0
Moat Score
NONE
4/9
Piotroski Score
-10.9
Altman Z-Score
Insider Signal
NEUTRAL
2 buys / 2 sells (90d)
Congress Signal
BUYING
2 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sebelius Kathleen | director | Buy | 56,818 | $50K | May 19, 2026 |
| Parikh Shamik J | officer | Sale | 45,887 | $41K | May 18, 2026 |
| Sander Dale A. | officer | Sale | 45,887 | $41K | May 18, 2026 |
| Constantino Michael T. | director | Buy | 11,000 | $10K | May 18, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
79.37%
FCF Growth YoY
-6.3%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for HUMA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:34:37 | $0.62 | 1,000 | $$620 | BUY |
| 14:34:30 | $0.62 | 8,200 | $$5K | BUY |
| 14:34:26 | $0.62 | 1,000 | $$620 | BUY |
| 14:34:22 | $0.62 | 3,700 | $$2K | BUY |
| 14:34:15 | $0.62 | 2,344 | $$1K | SELL |
5 dark pool trades shown · $$10K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Humacyte, Inc. (HUMA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Humacyte, Inc. (HUMA) is at $0.58, down 1.22% (-$0.01) at the Nov 12, 2026 close.
Latest HUMA news — Nov 11, 2026: Barclays keeps Equal-Weight on Humacyte, lifts price target to $0.6 · Nov 11, 2026: Humacyte Shares Findings on Bioengineered Blood Vessel at VEITH 2026
Humacyte shares surged 20.21% today, closing at $0.44 on heavy volume of over 16.5 million shares. The rally followed the company's announcement that hospitals ordering Symvess increased 44% to 49 in Q3 2026, signaling accelerating commercial adoption of its product.
The average analyst price target for HUMA is $1.25, ranging from $1 to $4, based on 7 analysts. Latest: Barclays initiates on Oct 7, 2026.
Analyst ratings for HUMA: 0 Buy, 15 Hold, 1 Sell — consensus Hold.
HUMA last reported on Aug 12, 2026: EPS -$0.16 vs -$0.11 expected — a miss of 41.1%.
HUMA does not currently pay a dividend.
Humacyte, Inc. reported $36M of debt and $80M of cash (Jun 30, 2026).
Support: $0.51, $0.39. Resistance: $0.62, $0.75, $0.87.
Insider activity: NEUTRAL, 2 buys and 2 sells in the last 90 days.
Nov 11, 2026: Barclays keeps Equal-Weight on Humacyte, lifts price target to $0.6 · Nov 11, 2026: Humacyte Shares Findings on Bioengineered Blood Vessel at VEITH 2026 · Nov 10, 2026: BTIG Reiterates Buy Rating on Humacyte With $2 Price Target